CODX — Co-Diagnostics, Inc.

—
Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1692415 ·
Last close
$0.20
Market Cap
$2.06M
52W High
$13.54
52W Low
$0.17
ADV30
3,905,024
Next earnings
2026-11-10
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 282,881 -20,463 -6,269,350 -6,306,408 12,791,848 714,803 3,366,569
Jun 2026 166,131 120,828 -6,200,783 -6,283,786 16,590,631 3,649,632 3,878,282
Mar 2026 145,954 -47,814 -9,208,411 -9,140,038 21,499,726 8,230,984 5,457,316
Dec 2025 263,922 121,526 -7,659,784 -25,745,725 24,742,585 11,884,607 4,113,921

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-26,882,599
Investing CF
$-654,722
Financing CF
$16,808,181
CapEx
$-307,268
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-11.19
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-102,103,771
Inventory
$672,950
Receivables
$51,828
ST Investments
$0
EBIT TTM
$-29,338,328
Pretax Income TTM
$-47,929,485
Interest Exp TTM
—
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$858,888
EBITDA
$-28,391,114
Free Cash Flow
$-15,207,230
Enterprise Value
$3,568,152
Total Cash
$714,803
Total Debt
$1,564,503
Shares Out
10,512,190
Trailing EPS
$-21.71
Book Value
$1.29
ROE
-192.8%
ROA
-63.7%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 622,489 -31,283,352 -46,895,936 24,742,585 4,113,921 20,628,664 -29,136,927
Dec 2024 3,915,160 -40,081,310 -37,639,008 63,563,158 9,688,001 53,875,157 -29,155,045
Dec 2023 6,812,038 -42,706,234 -35,332,865 95,320,660 9,307,045 86,013,615 -22,081,865
Dec 2022 34,218,209 -11,591,291 -14,238,249 123,086,281 8,566,287 114,519,994 6,568,737

TTM Snapshot

Revenues TTM
$721,387
NetIncome TTM
$-47,056,372
OpCashFlow TTM
—
Assets (Latest)
$16,590,631
Forward EPS
$-0.83

Peers — same industry

TickerNameMarket CapLastDaily %
AMIX Autonomix Medical, Inc. $2.21M $1.08 —
NUWE Nuwellis, Inc. $2.22M $4.10 —
NXL Nexalin Technology, Inc. $1.85M $1.50 —
BJDX Bluejay Diagnostics, Inc. $2.41M $2.15 —
DROR Dror Ortho-Design, Inc. $2.44M $0.00 —

News headlines (Yahoo Finance, 1h cache)

Co-Diagnostics Receives Logix Smart® ZDC Test Order from Peru Distributor as Dengue Cases Rise and Exhibits at MEDICA 2026 in Düsseldorf
2026-11-17 14:00 · Yahoo
Co-Diagnostics Reports Third Quarter 2026 Financial Results
2026-11-10 13:00 · Yahoo
Co-Diagnostics Announces Updated Third Quarter 2026 Earnings Release Date and Webcast
2026-11-05 22:00 · Yahoo
Co-Diagnostics to Participate in Three Global Tuberculosis Events in November as CoSara Advances Toward Anticipated India Launch
2026-11-05 14:00 · Yahoo
Co-Diagnostics Announces Third Quarter 2026 Earnings Release Date and Webcast
2026-10-29 13:15 · Yahoo
Co-Diagnostics Moves Closer to Commercial Tuberculosis Test Launch in India
2026-10-27 12:33 · Yahoo
Co-Diagnostics' Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
2026-10-20 13:15 · Yahoo
Co-Diagnostics Highlights PCR Platform Capabilities for Potential Plague Detection
2026-10-15 13:15 · Yahoo
Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe
2026-10-08 13:26 · Yahoo
Co-Diagnostics Highlights Vector Smart® Momentum Following New Federal Initiative on Vector-Borne Disease
2026-10-07 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.